The abundance of Interleukin-22, 37, and 38 post-vaccination and following COVID-19 recuperation
Main Article Content
Keywords
COVID-19 Recovery; IL-22; IL-37; IL-38; Sinopharm; Pfizer-BioNTech; Vaccine.
Abstract
The SARS-CoV-2 virus causes a contagious disease known as Coronavirus Disease 2019 (COVID19). It began spreading globally in 2019 and is still producing pandemics today. Different COVID-19 vaccinations offer protection against this illness. Pfizer-BioNTech and Sinopharm were the two vaccine manufacturers with the highest usage in Iraq. Both vaccines use a different method to activate the immune system. This study seeks to compare the IL-22, IL-37, and IL-38 levels in those who received either the Sinopharm or the Pfizer-BioNTech COVID-19 vaccination. IL-22, IL-37, IL-38 levels have been shown to be upregulated in COVID-19 patients. In this study, IL-22, IL-37, and IL38 levels were tested in 80 healthy controls and 100 COVID-19 patients 14–21 days after recovery. Additionally, people who received the Sinopharm or Pfizer-BioNTech vaccine (50 each) were monitored 21 days after the first dosage and 21 days after the second dose. In comparison to controls, serum levels were noticeably higher in recovered patients. Except for the first dosage of Pfizer
BioNTech, the first and second doses of Sinopharm and Pfizer BioNTech were linked to considerably higher levels of IL-22, IL-37, and IL-38 compared to controls or recovered patients. where IL-22, IL37, and IL-38 levels did not show significant differences compared to recovered patients. In conclusion, lower IL-37 and IL-38 molecule levels were linked to recovery from COVID-19, although these levels remained considerably greater in recovered patients compared to uninfected controls. Vaccination with Sinopharm or Pfizer-BioNTech confirmed the up-regulating effects of SARS-CoV2 on IL-22, IL-37, and IL-38 levels.
References
2. Hu, B., Guo, H., Zhou, P., Shi, Z.L., 2021. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-020-00459-7
3. World Health Organization & United Nations Children’s Fund (UNICEF) COVID-19 Vaccination: Supply and Logistics Guidance:
Interim Guidance, 12 February 2021, World Health Organization, https://apps.who.int/iris/handle/10665/339561.
4. Hamed RM, Ali RA, Nori W. Hesitancy and acceptance of COVID-19 vaccines among Iraqi medical students: A cross-sectional study. Journal
of Emergency Medicine, Trauma & Acute Care. 2022(6):10 https://doi.org/10.5339/jemtac.2022. aimco.10.
5. Al Khames Aga, Q.A., Alkhaffaf, W.H., Hatem, T.H., Nassir, K.F., Batineh, Y., Dahham, A.T., Shaban, D., Al Khames Aga, L.A., Agha, M.Y.R.,
Traqchi, M., 2021. Safety of COVID-19 vaccines. J. Med. Virol. 93, 6588–6594. https://doi.org/10.1002/jmv.27214
6. Hadj Hassine, I., 2022. Covid-19 vaccines and variants of concern: A review. Rev. Med. Virol. 32, e2313. https://doi.org/10.1002/rmv.2313
7. Sharma, K., Koirala, A., Nicolopoulos, K., Chiu, C., Wood, N., Britton, P.N., 2021. Vaccines for COVID-19: Where do we stand in 2021?
Paediatr. Respir. Rev. 39, 22–31. https://doi.org/10.1016/j.prrv.2021.07.001
8. Wong, R.S.Y., 2021. Inflammation in COVID19: from pathogenesis to treatment. Int. J. Clin. Exp. Pathol. 14, 831–844.
9. Darif, D., Hammi, I., Kihel, A., El Idrissi Saik, I., Guessous, F., Akarid, K., 2021. The proinflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb. Pathog. 153, 104799.
10. Notz, Q., Schmalzing, M., Wedekink, F., Schlesinger, T., Gernert, M., Herrmann, J., Sorger, L., Weismann, D., Schmid, B., Sitter, M., Schlegel, N., Kranke, P., Wischhusen, J., Meybohm, P., Lotz, C., 2020. Pro- and AntiInflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. Front. Immunol. 11, 581338. https://doi.org/10.3389/fimmu.2020.581338
11. Ahmed, A.A., Ad’hiah, A.H., 2021. Interleukin37 is down-regulated in serum of patients with severe coronavirus disease 2019 (COVID-19).
Cytokine 148, 155702. https://doi.org/10.1016/j.cyto.2021.155702
12. Ahmed Mostafa, G., Mohamed Ibrahim, H., Al Sayed Shehab, A., Mohamed Magdy, S., AboAbdoun Soliman, N., Fathy El-Sherif, D., 2022. Up-regulated serum levels of interleukin (IL)-17A and IL-22 in Egyptian pediatric patients with COVID-19 and MIS-C: Relation to the disease outcome. Cytokine 154, 155870. https://doi.org/10.1016/j.cyto.2022.155870
13. Al-bassam, W.W., Al-Karaawi, I.A., Sharquie, I.K., Ad’hiah, A.H., 2022. Evaluation of interleukin-38 levels in serum of patients with coronavirus disease 2019. J. Med. Virol. 94, 3642–3652. https://doi.org/10.1002/jmv.27762
14. Su, Z., Tao, X., 2021. Current Understanding of IL-37 in Human Health and Disease. Front. Immunol. 12, 696605. https://doi.org/10.3389/fimmu.2021.696605
15. Li, A., Ling, Y., Song, Z., Cheng, X., DIng, L., Jiang, R., Fu, W., Liu, Y., Hu, H., Yuan, S., Chen, J., Zhu, C., Fan, J., Wang, J., Jin, Y., Zhang, M.,
Zhu, L., Sun, P., Zhang, Linxia, Qin, R., Zhang, W., Qiu, C., Shen, Y., Zhang, Lin, Shi, Z., Zhao, C., Zhu, T., Lu, H., Zhang, X., Xu, J., 2021. Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. 223, 568–580. https://doi.org/10.1093/INFDIS/JIAA713
16. Fazeli, P., Saeidnia, M., Erfani, M., Kalani, M., 2022. An overview of the biological and multifunctional roles of IL-38 in different infectious diseases and COVID-19. Immunol. Res. 70, 316–324. https://doi.org/10.1007/s12026-022-09275-y
17. Gao, X., Chan, P.K.S., Lui, G.C.Y., Hui, D.S.C., Chu, I.M.T., Sun, X., Tsang, M.S.M., Chan, B.C.L., Lam, C.W.K., Wong, C.K., 2021. Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections. Cell Death Dis. 12, 53. https://doi.org/10.1038/s41419-020-03283-2
18. Arshad, T., Mansur, F., Palek, R., Manzoor, S., Liska, V., 2020. A Double Edged Sword Role of Interleukin-22 in Wound Healing and Tissue Regeneration. Front. Immunol. 11, 2148. https://doi.org/10.3389/fimmu.2020.02148
19. Albayrak, N., Orte Cano, C., Karimi, S., Dogahe, D., Van Praet, A., Godefroid, A., Del Marmol, V., Grimaldi, D., Bondue, B., Van Vooren, J.P., Mascart, F., Corbière, V., 2022. Distinct Expression Patterns of Interleukin-22 Receptor 1 on Blood Hematopoietic Cells in SARS-CoV-2
Infection. Front. Immunol. 13, 769839. https://doi.org/10.3389/fimmu.2022.769839
20. Nori W, Hamed RM, Akram W, Munshid MC. The dilemma of COVID-19 diagnosis in pregnancy. Immunopathol Persa. 2022;e32416.
doi: 10.34172/ipp.2022.32416
21. Ahmed Saeed H, Mohammed Ali Jassim M, Mahmood M M, Saad Hanfoosh H. A Glance at Coronavirus in General Population of ThiQar and Al- Muthanna Provinces. Health Education and Health Promotion. 2022;10(3):587-591.
22. Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, et al. Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease
2019 in China. J Infect Dis (2020) 222(5):746–54. doi: 10.1093/infdis/jiaa363.
23. S. Ivanov, J. Renneson, J. Fontaine, A. Barthelemy, C. Paget, E.M. Fernandez, F. Blanc, C. De Trez, L. Van Maele, L. Dumoutier, M.-R.
Huerre, G. Eberl, M. SiTahar, P. Gosset, J.C. Renauld, J.C. Sirard, C. Faveeuw, F. Trottein, Interleukin-22 reduces lung inflammation during
influenza A virus infection and protects against secondary bacterial infection, J. Virol. 87 (12) (2013) 6911–6924.
24. Alcorn JF (2020) IL-22 Plays a Critical Role in Maintaining Epithelial Integrity During Pulmonary Infection. Front. Immunol. 11:1160. doi: 10.3389/fimmu.2020.01160
25. D. Wu, X.O. Yang, TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib, J. Microbiol. Immunol.
Infect. 53 (3) (2020) 368–370.
26. Behnsen J, Jellbauer S, Wong CP et al. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria.
Immunity 2014;40:262–73.
27. Liu W, Zhang Q, Chen J, et al. Detection of CoV19 in children in early January 2020 in Wuhan, China. N Engl J Med 2020; doi: 10.1056/NEJMc2003717
28. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, et al. (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11: 1014-1022.
29. Conti P, Lauritano D, Caraffa Al, et al. Microglia and mast cells generate proinflammatory cytokines in the brain and worsen inflammatory
state: Suppressor effect of IL-37. Eur J Pharmacol 2020; 875:173035.
30. Gao X, Chan PKS, Lui GCY, Hui DSC, Chu IM, Sun X, Tsang MS, Chan BCL, Lam CW, Wong CK. Interleukin-38 ameliorates poly(I:C) induced lung infammation: therapeutic implications in respiratory viral infections. Cell Death Dis. 2021;12(1):53. https:// doi.org/10.1038/s41419-020-03283-2.
31. Mahmood MM. No to the Herd Immunity against Novel Coronavirus (SARS-Cov-2) withoutVaccination. Pharm Res 2020, 4(2): 000204.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.